Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India

Clinical Infectious Diseases

Volumn 54, Issue 7, 2012, Pages 995-1000

  Saravanan, Shanmugam ^a   Vidya, Madhavan ^a   Balakrishnan, Pachamuthu ^a   Kantor, Rami ^b   Solomon, Sunil S ^a   Katzenstein, David ^c   Kumarasamy, Nagalingeswaran ^a   Yeptomi, Tokugha ^a   Sivamalar, Sathasivam ^a   Rifkin, Samara ^b   Mayer, Kenneth H ^b   Solomon, Suniti ^a  

^a The Voluntary Health Services Chennai   (India)

^b BROWN UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INDIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; MUTATION, MISSENSE; SULFONAMIDES; VIRAL LOAD; VIRAL PROTEINS;

EID: 84858124127     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir967     Document Type: Article

References (43)

1. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:8270-6. (Pubitemid 26378401)
2. Hertogs K, Bloor S, Kemp SD, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor crossresistance: a survey of over 6000 samples. AIDS 2000; 14:1203-10. (Pubitemid 30420664)
3. Miller V. Resistance to protease inhibitors. J Acquir Immune Defic Syndr 2001; 26:S34-50.
4. Kandathil AJ, Kannangai R, Verghese VP, et al. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India. Indian JMed Microbiol 2009; 27:231-6.
5. Gupta A, Saple DG, Nadkarni G, et al. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India. AIDS Res Hum Retroviruses 2010; 26:25-31.
6. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35. (Pubitemid 38269279)
7. Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 1995; 270:21433-6.
8. Lin Y, Lin X, Hong L, et al. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance. Biochemistry 1995; 34:1143-52.
9. Hertogs K, Van Houtte M, Larder BA. Testing for HIV-1 drug resistance: new development and clinical implications. Rec Res Dev Antimicrob Agents Chemother 1999; 3:83-104.
10. Kemper CA, Witt MD, Keiser PH, et al. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS 2001; 15:609-15. (Pubitemid 32281356)
11. Kozal M. Cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDs 2004; 18:199-208. (Pubitemid 38552652)
12. Smith DM, Schooley RT. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008; 46: 1598-600.
13. Balakrishnan P, Solomon S, Kumarasamy N, Mayer KH. Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. Indian J Med Res 2005; 121:345-55. (Pubitemid 40691368)
14. Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther 2009; 14:1005-9.
15. Hira SK, Panchal K, Parmar PA, Bhatia VP. High resistance to antiretroviral drugs: the Indian experience. Int J STD AIDS 2004; 15:173-7. (Pubitemid 38647179)
16. Deshpande A, Jauvin V, Magnin N, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007; 23:335-40. (Pubitemid 46418349)
17. Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007; 23:1303-8. (Pubitemid 350014773)
18. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R, Pillay D. Resistanceassociated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 2001; 39:2652-4. (Pubitemid 32606251)
19. Kuiken C, Foley B, Freed E, et al. HIV sequence compendium, Los Alamos National Laboratory, US. J Clin Microbiol 2002; 39:2652-4.
20. Gupta SB, Pujari SN, Joshi SR, Patel AK. AIDS Society of India Guidelines Development Committee. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS society of India. J Assoc Physicians India 2006; 54:57-74. (Pubitemid 43036788)
21. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-9. (Pubitemid 47236692)
22. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010; 18:156-63.
23. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 version). Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed 5 December 2010.
24. Joly V, Descamps D, Peytavin G, et al. Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 2004; 48:172-5. (Pubitemid 38040194)
25. Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, Ló pez-Gal?́ndez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002; 83:93-101. (Pubitemid 34030813)
26. Abecasis AB, Deforche K, Snoeck J, et al. Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G. AIDS 2005; 19:1799-806.
27. Grossman Z, Paxinos EE, Averbuch D, et al. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob Agents Chemother 2004; 48:2159-65. (Pubitemid 38691614)
28. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-6. (Pubitemid 26225091)
29. de Meyer S, Vangeneugden T, van Baelen B, et al. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008; 24:379-88. (Pubitemid 351457745)
30. Mammano F, Trouplin V, Zennou V, Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol 2000; 74:8524-31. (Pubitemid 30666703)
31. ShaferRW, Kantor R, GonzalesMJ. The genetic basis ofHIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev 2000; 2: 211-228. (Pubitemid 32380985)
32. Mo H, Parkin N, Stewart KD, et al. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob Agents Chemother 2007; 51:732-5. (Pubitemid 46185296)
33. Vermeiren H, Van Craenenbroeck E, Alen P, Bacheler L, Picchio G, Lecocq P. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007; 145:47-55. (Pubitemid 47247892)
34. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-9. (Pubitemid 32738004)
35. Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49:1441-9.
36. Balakrishnan P, Kumarasamy N, Kantor R, et al. HIV type 1 genotypic variation in an antiretroviral treatment-na?̈ve population in southern India. AIDS Res Hum Retroviruses 2005; 21:301-5. (Pubitemid 40632362)
37. Lall M, Gupta RM, Sen S, Kapila K, Tripathy SP, Paranjape RS. Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses 2008; 24:987-90.
38. Deshpande A,Recordon-Pinson P,Deshmukh R,et al.Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations.AIDS Res Hum Retroviruses.2004,20, 1032-5. (Pubitemid 39369712)
39. Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum Retroviruses 2009; 25:1179-85.
40. Eshleman SH, Hudelson SE, Gupta A, et al. Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res Hum Retroviruses 2005; 21:93-7. (Pubitemid 40179805)
41. Chaturbhuj DN, Hingankar NK, Srikantiah P, et al. Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses 2010; 26:927-32.
42. Arora SK, Gupta S, Toor JS, Singla A. Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res HumRetroviruses 2008; 24:125-30. (Pubitemid 351282103)
43. Neogi U, Prarthana BS, Gupta S, et al. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviralnaive individuals in Bangalore, India. AIDS Res Hum Retroviruses 2010; 26. 1097-101.